Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy
Bowen Li, Haoran Xu, Wenjun Zhang, Jing Yang · 2026
Read Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy by Bowen Li, Haoran Xu, Wenjun Zhang, Jing Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13226132.txt.
Description
Bowen Li and three co-authors described in 2026 how to strip a brake from engineered cancer-killing cells. CAR-T therapy transformed care for blood cancers, yet about sixty percent of patients relapse. One cause: some infused cells turn regulatory, becoming CAR-Tregs that suppress their effector teammates with calming signals. As few as five percent of these cells can doom treatment in animal models.
Screening over 3,000 compounds surfaced a natural product from a traditional Chinese herb. At a clinic-ready dose it cut the regulatory share by about forty percent and sharpened killing, without harming cell health. Tracing its target with a tagged probe pointed to a surface receptor for adenosine. The compound is already at clinical stage for other uses.
Catalog record
| CREATOR | Bowen Li, Haoran Xu, Wenjun Zhang, Jing Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |